Search results
Results from the WOW.Com Content Network
2C-B (4-bromo-2,5-dimethoxyphenethylamine), also known as Nexus, is a synthetic psychedelic drug of the 2C family, mainly used as a recreational drug. [ 2 ] [ 1 ] [ 4 ] It was first synthesized by Alexander Shulgin in 1974 for use in psychotherapy .
The following is a list of psychedelic drugs of various chemical classes, including both naturally occurring and synthetic compounds. Serotonergic psychedelics are usually considered the "classical" psychedelics [dubious – discuss], whereas the other classes are often seen as having only secondary psychedelic properties; nonetheless all of the compounds listed here are considered ...
2C-B-aminorex (2C-B-AR) is a recreational designer drug with psychedelic effects. It is a substituted aminorex derivative which was first identified in Sweden in June 2019. [ 1 ] Structurally, it is a hybrid of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) and aminorex.
2C (2C-x) is a general name for the family of psychedelic phenethylamines containing methoxy groups on the 2 and 5 positions of a benzene ring. [ 1 ] [ 2 ] [ 3 ] Most of these compounds also carry lipophilic substituents at the 4 position, usually resulting in more potent and more metabolically stable and longer acting compounds.
The full name of the chemical is 2-(8-bromo-2,3,6,7-tetrahydrofuro[2,3-f] [1]benzofuran-4-yl)ethanamine. It has been subject of little formal study, but its appearance as a designer drug has led the DEA to release analytical results for 2C-B-FLY and several related compounds.
This page was last edited on 14 February 2024, at 07:27 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
2C-B-DRAGONFLY (2C-B-DFLY) is a recreational designer drug with psychedelic effects. It can be regarded as the fully aromatic derivative of 2C-B-FLY. 2C-B-DRAGONFLY is stronger than 2C-B or 2C-B-FLY with around 2–3x the potency of 2C-B in animal studies, demonstrating the importance of the fully aromatic benzodifuran ring system for optimum receptor binding at 5-HT 2A, but it is still ...
TCB-2 is a hallucinogen discovered in 2006 by Thomas McLean working in the lab of David Nichols at Purdue University. [1] It is a conformationally -restricted derivative of the phenethylamine 2C-B , also a hallucinogen, and acts as a potent agonist for the 5-HT 2A and 5-HT 2C receptors with a K i of 0.26 nM at the human 5-HT 2A receptor.